Covered recipient · General Payments record
MATTHEW BUDOFF
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$558,227.34
432 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $488,340.50 | 222 |
| Consulting Fee | $31,028.25 | 13 |
| Travel and Lodging | $22,657.31 | 82 |
| Honoraria | $8,750.00 | 3 |
| Food and Beverage | $7,253.28 | 110 |
| Education | $198.00 | 2 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Esperion Therapeutics, Inc. | $147,952.87 | 108 |
| Lilly USA, LLC | $123,675.00 | 90 |
| Novo Nordisk Inc | $90,130.06 | 43 |
| AstraZeneca Pharmaceuticals LP | $63,245.63 | 64 |
| Merck Sharp & Dohme Corporation | $43,739.85 | 32 |
| Amgen Inc. | $21,382.08 | 20 |
| Amarin Pharma Inc. | $16,650.00 | 10 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $16,636.19 | 14 |
| Regeneron Healthcare Solutions, Inc. | $12,137.03 | 8 |
| Eli Lilly and Company | $6,000.00 | 2 |
| FUKUDA DENSHI Co., Ltd. | $5,750.00 | 2 |
| PFIZER INC. | $3,385.06 | 6 |
| Kowa Pharmaceuticals America, Inc. | $3,352.44 | 4 |
| Novartis Pharmaceuticals Corporation | $1,691.63 | 4 |
| GE HEALTHCARE | $1,600.00 | 1 |
| Astellas Pharma US Inc | $213.42 | 3 |
| Abbott Laboratories | $180.96 | 1 |
| Janssen Pharmaceuticals, Inc | $170.16 | 8 |
| Regeneron Pharmaceuticals, Inc. | $122.20 | 1 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $65.62 | 4 |
| Actelion Pharmaceuticals US, Inc. | $60.36 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $26.99 | 1 |
| E.R. Squibb & Sons, L.L.C. | $23.47 | 1 |
| Medtronic, Inc. | $20.28 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $16.04 | 1 |
Page 3 of 9; records 101–150 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MATTHEW BUDOFF
NPI 1811967433 · CMS profile ID 127894
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
TORRANCE, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 9; records 101–150 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MATTHEW BUDOFF, NPI 1811967433, CMS profile ID 127894, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 9; records 101–150 of 432 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1811967433?year=2021&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
432 matching records · $558,227.34 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 432.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corporation | $3,815.00 | 09/08/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848310099 | CMS |
| Amgen Inc. | $41.44 | 09/07/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599627 | CMS |
| Amgen Inc. | $2,800.00 | 09/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599635 | CMS |
| Amgen Inc. | $467.00 | 09/07/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599651 | CMS |
| Novartis Pharmaceuticals Corporation | $1,623.00 | 09/07/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 812621315 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,200.00 | 09/03/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 763412940 | CMS |
| Merck Sharp & Dohme Corporation | $689.00 | 09/02/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848479317 | CMS |
| Amgen Inc. | $59.36 | 09/01/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599623 | CMS |
| Amgen Inc. | $2,800.00 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599631 | CMS |
| Amgen Inc. | $467.00 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599647 | CMS |
| Esperion Therapeutics, Inc. | $3,400.00 | 09/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255531 | CMS |
| Amgen Inc. | $95.33 | 08/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599643 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,340.00 | 08/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 809562635 | CMS |
| Amgen Inc. | $114.07 | 08/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599639 | CMS |
| GE HEALTHCARE | $1,600.00 | 08/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 837875209 | CMS |
| Novo Nordisk Inc | $2,156.25 | 08/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810847437 | CMS |
| Novo Nordisk Inc | $2,587.50 | 08/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811047883 | CMS |
| Novo Nordisk Inc | $431.25 | 08/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811599805 | CMS |
| Esperion Therapeutics, Inc. | $113.86 | 08/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255515 | CMS |
| Esperion Therapeutics, Inc. | $24.58 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255519 | CMS |
| Esperion Therapeutics, Inc. | $277.96 | 08/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255521 | CMS |
| Esperion Therapeutics, Inc. | $192.97 | 08/23/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255525 | CMS |
| Esperion Therapeutics, Inc. | $13.99 | 08/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838255527 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,300.00 | 08/18/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829764079 | CMS |
| Amgen Inc. | $32.37 | 08/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825599595 | CMS |
| Lilly USA, LLC | $1,200.00 | 08/12/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818610503 | CMS |
| Astellas Pharma US Inc | $15.42 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 821273089 | CMS |
| AstraZeneca Pharmaceuticals LP | $276.64 | 08/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829543479 | CMS |
| AstraZeneca Pharmaceuticals LP | $196.40 | 08/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829669299 | CMS |
| AstraZeneca Pharmaceuticals LP | $134.62 | 08/10/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829719407 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.87 | 08/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 830095855 | CMS |
| BOSTON SCIENTIFIC CORPORATION | $16.04 | 08/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 777725277 | CMS |
| Lilly USA, LLC | $300.00 | 08/09/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818602387 | CMS |
| Kowa Pharmaceuticals America, Inc. | $3,000.00 | 08/05/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805435697 | CMS |
| Kowa Pharmaceuticals America, Inc. | $168.40 | 08/05/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805435703 | CMS |
| Lilly USA, LLC | $1,200.00 | 07/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818657177 | CMS |
| PFIZER INC. | $19.73 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832753133 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,200.00 | 07/25/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829384917 | CMS |
| Novo Nordisk Inc | $4,875.00 | 07/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811242507 | CMS |
| Novo Nordisk Inc | $22.40 | 07/22/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811308855 | CMS |
| Novo Nordisk Inc | $112.81 | 07/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811598397 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829271139 | CMS |
| AstraZeneca Pharmaceuticals LP | $44.80 | 07/21/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829482989 | CMS |
| Lilly USA, LLC | $1,200.00 | 07/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818641443 | CMS |
| Novo Nordisk Inc | $4,875.00 | 07/20/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811242503 | CMS |
| Novo Nordisk Inc | $125.00 | 07/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811308849 | CMS |
| Lilly USA, LLC | $1,500.00 | 07/15/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818587219 | CMS |
| Novo Nordisk Inc | $104.16 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810780013 | CMS |
| Novo Nordisk Inc | $7,687.50 | 07/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 810847431 | CMS |
| Novo Nordisk Inc | $9.15 | 07/15/2021 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 811308839 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $19,093.06 | 9 |
| PY2025 | Principal investigator | $1,159,945.76 | 40 |
| PY2024 | Recipient | $474,548.50 | 3 |
| PY2024 | Principal investigator | $876,843.21 | 71 |
| PY2023 | Recipient | $65,346.50 | 3 |
| PY2023 | Principal investigator | $910,851.85 | 113 |
| PY2022 | Recipient | $1,794.49 | 8 |
| PY2022 | Principal investigator | $783,031.83 | 111 |
| PY2021 | Recipient | $940.00 | 1 |
| PY2021 | Principal investigator | $1,077,613.94 | 313 |
| PY2020 | Recipient | $21,712.08 | 10 |
| PY2020 | Principal investigator | $1,440,514.07 | 410 |
| PY2019 | Principal investigator | $1,441,179.18 | 581 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
49 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $9,108.34 | 12/31/2025 | Non-covered Recipient Entity Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction | No dispute reported | 06/30/2026 | 1232920281 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $200.00 | 12/23/2025 | Non-covered Recipient Entity Lundquist Inst For Biomed At Harbor-ucla Medical | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV | No dispute reported | 06/30/2026 | 1225415010 |
| Recipient | Cleerly, Inc. | $750.00 | 12/05/2025 | Covered Recipient Physician | TRANSFORM | No dispute reported | 06/30/2026 | 1241147830 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,100.00 | 12/03/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA | A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event | No dispute reported | 06/30/2026 | 1185552741 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,900.00 | 11/30/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185552743 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,000.00 | 11/30/2025 | Non-covered Recipient Entity LAYOUS MEDICAL GROUP | Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185552747 |
| Principal investigator 1 | Cleerly, Inc. | $1,345.00 | 11/26/2025 | Non-covered Recipient Entity The Lunquist Institute | Confirm2 | No dispute reported | 06/30/2026 | 1241147496 |
| Principal investigator 1 | Novo Nordisk AS | $1,333.32 | 10/31/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | NN9535-4321 | No dispute reported | 06/30/2026 | 1213747164 |
| Recipient | Novartis Pharma AG | $284.36 | 10/29/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109417 |
| Recipient | Novartis Pharma AG | $484.08 | 10/29/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109419 |
| Recipient | Novartis Pharma AG | $188.35 | 10/29/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109421 |
| Recipient | Novartis Pharma AG | $184.27 | 10/29/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109423 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $203.67 | 10/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA AT LOS ANGELES | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190302351 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $100.00 | 10/21/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246789500 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $9,100.00 | 10/16/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246789371 |
| Principal investigator 1 | GE HEALTHCARE | $91,518.11 | 10/15/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 20HC-G-Cardiac CT Deblooming | No dispute reported | 06/30/2026 | 1244366631 |
| Principal investigator 1 | GE HEALTHCARE | $83,182.54 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 20HC-G-Cardiac CT Deblooming | No dispute reported | 06/30/2026 | 1244366627 |
| Principal investigator 1 | GE HEALTHCARE | $140,180.56 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | 20HC-G-Cardiac CT Deblooming | No dispute reported | 06/30/2026 | 1244366629 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $650.00 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788352 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $675.00 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788356 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,000.00 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788359 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,275.00 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788363 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,380.00 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788368 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $13,770.39 | 10/08/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246788371 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,836.61 | 09/02/2025 | Non-covered Recipient Entity HARBOR - UCLA MEDICAL CENTER | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190301467 |
| Recipient | Novartis Pharma AG | $92.55 | 08/29/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109839 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $4,300.00 | 08/22/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA | a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure | No dispute reported | 06/30/2026 | 1185552737 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $3,469.02 | 08/06/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246786044 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $300.00 | 07/10/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246785187 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $1,500.00 | 07/10/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER | IS354CS9 | No dispute reported | 06/30/2026 | 1246785191 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $9,375.30 | 06/30/2025 | Non-covered Recipient Entity Lundquist Inst For Biomed At Harbor-ucla Medical | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV | No dispute reported | 06/30/2026 | 1225412308 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,520.00 | 05/08/2025 | Non-covered Recipient Entity Lundquist Inst For Biomed At Harbor-ucla Medical | A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LV | No dispute reported | 06/30/2026 | 1225412712 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $344.00 | 04/30/2025 | Non-covered Recipient Entity Lundquist Inst For Biomed At Harbor-ucla Medical | BAY 948862, A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fracti | No dispute reported | 06/30/2026 | 1225403743 |
| Principal investigator 1 | Amgen Inc. | $36,550.00 | 04/24/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246643704 |
| Recipient | Amgen Inc. | $2,909.45 | 03/31/2025 | Covered Recipient Physician | P4 Global Vesalius Real | No dispute reported | 06/30/2026 | 1246637206 |
| Principal investigator 1 | Novo Nordisk AS | $9,812.39 | 03/31/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | EX9924-4473 | No dispute reported | 06/30/2026 | 1213814680 |
| Principal investigator 1 | Cleerly, Inc. | $119.49 | 03/24/2025 | Non-covered Recipient Entity The Lunquist Institute | Confirm2 | No dispute reported | 06/30/2026 | 1241147438 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,152.60 | 03/24/2025 | Non-covered Recipient Entity HARBOR - UCLA MEDICAL CENTER | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190308160 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58,570.99 | 03/12/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE BIOMED AT HARBOR | A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag | No dispute reported | 06/30/2026 | 1190305617 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $25,434.78 | 02/27/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190301891 |
| Principal investigator 1 | Novo Nordisk AS | $1,700.00 | 02/21/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | EX9924-4473 | No dispute reported | 06/30/2026 | 1213744553 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $2,578.50 | 02/05/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR UCLA | REALIZE-K Phase IV, randomized, double-blind, placebo-controlled, parallel-group trial evaluating Sodium Zirconium Cyclosilicate (SZC) for the management of hyperkalemia in patients with symptomatic heart failure with reduced ejection fraction, chronic kidney disease and receiving spironolactone | No dispute reported | 06/30/2026 | 1185552739 |
| Principal investigator 1 | Amgen Inc. | $28,026.40 | 01/30/2025 | Non-covered Recipient Entity HARBOR UNIVERSITY OF CALIFORNIA LOS ANGELES MEDICAL CENTER | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246642048 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,748.20 | 01/30/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190301889 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $27,032.00 | 01/30/2025 | Non-covered Recipient Entity THE LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION | A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag | No dispute reported | 06/30/2026 | 1190301893 |
| Recipient | Novartis Pharma AG | $4,200.00 | 01/28/2025 | Covered Recipient Physician | CKJX839D12303 | No dispute reported | 06/30/2026 | 1248109841 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $101,683.95 | 01/27/2025 | Non-covered Recipient Entity UNIVERSITY OF CALIFORNIA AT LOS ANGELES | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190302551 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $409,869.60 | 01/06/2025 | Non-covered Recipient Entity LUNDQUIST INSTITUTE BIOMED AT HARBOR | Imaging Long/term study of Inclisiran on Atherosclerotic Disease (ILIAD) Trial | No dispute reported | 06/30/2026 | 1190305615 |
| Recipient | Canon Medical Informatics, Inc. | $10,000.00 | 01/01/2025 | Covered Recipient Physician | Cardiac Analysis | No dispute reported | 06/30/2026 | 1254963070 |